Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma

Vaccination of Lymphoma Patients With Dendritic Cell-lymphoma Cell Hybrids and Dendritic Cells Pulsed With Tumor Lysates

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00937183

Enrollment

Registered

2009-07-10

Start date

2003-09-30

Completion date

2017-12-31

Last updated

2019-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm

Keywords

dendritic cell vaccine, tumor cell lysate, lymphoma

Brief summary

RATIONALE: Biological therapies, such as a dendritic cell vaccine made with a patient's cancer cells, may stimulate the immune system in different ways and stop cancer cells from growing. PURPOSE: This phase I/II trial is studying the side effects of dendritic cell vaccine and to see how well it works in treating patients with indolent B-cell lymphoma or multiple myeloma.

Detailed description

OBJECTIVES: * Evaluation of feasibility of dendritic cell (DC)-based vaccination program using autologous tumor cells and/or lysates in patients with indolent B cell lymphomas or multiple myeloma as an adjuvant therapy to induce immune response in remission after cytoreductive treatment. * Evaluation of the immune response of patients treated with this regimen. * Evaluation the progression-free survival of patients treated this regimen. * Evaluate the adverse events of this regimen in these patients. OUTLINE: Patients receive intranodal (under ultrasound guidance) or subcutaneous vaccinations of adjuvant electrofusion hybrids of autologous dendritic cells (DC) with autologous lymphoma cells, electrofusion hybrids of allogeneic DC with autologous lymphoma cells, and/or autologous DC pulsed with autologous tumor lysate cells in weeks 0, 2, 4, 8, 12, 18, 26, and 50.

Interventions

BIOLOGICALautologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine

BIOLOGICALautologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine

BIOLOGICALautologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of 1 of the following: * Mantle cell lymphoma * Marginal zone lymphoma * Follicular lymphoma * Small lymphocytic lymphoma/chronic lymphocytic leukemia * Multiple myeloma * Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia * Diffuse large B-cell lymphoma * Adequate sample size and lymphoma cell content in the fresh tissue collected * No bulky or progressive disease PATIENT CHARACTERISTICS: * Life expectancy \> 3 months * No evidence of lung, heart, liver, or renal failure or severe neurologic disorder * No autoimmune disease or atopic allergy * No HIV positivity * No other malignancy PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame
Immune response	—
Progression-free survival	—
Adverse events	—

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026